Nurtec® ODT (rimegepant) orally disintegrating tablets 75 mg

YOU'RE INVITED • LIVE SPEAKER PROGRAM

Tailor Migraine Management With the Flexibility of an Oral CGRP Receptor Antagonist

Expand your understanding of Nurtec ODT for the preventive treatment of episodic migraine at this engaging live presentation with the latest clinical data and real patient cases.

Presented By:

Samantha Winzenread, PA

Date and Time

Tuesday, November 17, 2026
06:30 PM Eastern Time

Location

Stella's Southern Bistro
684 Fairview Rd.
Simpsonville, South Carolina 29680
(864) 757-1212

Register Now!

Please RSVP for this event by scanning the QR code or visiting:

https://myattendeeresource.com/pfizer/261117-Pfizer-100

If you have any questions, please contact your sales representative.

Please reach out to:
Sonya Hunter
sonya.hunter@pfizer.com

with any questions.

Continuing medical education (CME) credits are not available for this program.

Speaker is paid by Pfizer Inc.

INDICATIONS

Nurtec ODT is indicated in adults for the:

- acute treatment of migraine with or without aura
- preventive treatment of episodic migraine

IMPORTANT SAFETY INFORMATION

Contraindications: Hypersensitivity to Nurtec ODT or any of its components.

Warnings and Precautions

Hypersensitivity Reactions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included anaphylaxis, dyspnea, and rash and can occur days after administration.

ODT, orally disintegrating tablet.

Please see additional Important Safety Information for Nurtec ODT on the next page.

Please click here for full Prescribing Information.

Nurtec® ODT (rimegepant) orally disintegrating tablets 75 mg

IMPORTANT SAFETY INFORMATION (CONT'D)

Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists, including Nurtec ODT, in the postmarketing setting.

Monitor patients for new-onset hypertension or worsening of pre-existing hypertension and consider whether discontinuation is warranted.

Raynaud's Phenomenon: Development of Raynaud's phenomenon and recurrence or worsening of pre-existing Raynaud's phenomenon have been reported in the postmarketing setting following the use of CGRP antagonists, including Nurtec ODT.

If signs or symptoms of Raynaud's phenomenon develop, discontinue Nurtec ODT. Patients should be evaluated by a healthcare provider if symptoms do not resolve. Patients with a history of Raynaud's phenomenon should be monitored for and informed about the possibility of worsening or recurrence of signs and symptoms.

Adverse Reactions: The most common adverse reactions for Nurtec ODT vs placebo were nausea (2.7% vs 0.8%) and abdominal pain/dyspepsia (2.4% vs 0.8%).

Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4 or strong or moderate inducers of CYP3A. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4 or potent inhibitors of P-gp.

Use in Specific Populations: *Pregnancy:* It is not known if Nurtec ODT can harm an unborn baby. *Lactation:* The transfer of rimegepant into breast milk is low (<1%). *Hepatic impairment:* Avoid use of Nurtec ODT in persons with severe hepatic impairment. *Renal impairment:* Avoid use in patients with end-stage renal disease.

Please click here for full Prescribing Information.

Because late arrivals may be prohibited from participating in the program, please make every effort to arrive by the designated start time.

You are expected to remain for the duration of the program.

Notice: Pfizer is committed to the appropriate marketing of its products to ensure that interactions with HCPs are professional exchanges designed to benefit patients and enhance the practice of medicine. All Pfizer-sponsored programs are conducted in accordance with PhRMA Code principles to address a bona fide educational need with appropriate attendees in a venue and manner conducive to informational exchange.

State and Federal Employees: State and federal laws and regulations may carry additional restrictions. By attending this event, you confirm that you have obtained any necessary approvals from your employer.

Public Disclosures: Pfizer reports payment and transfer of value data as required by federal and state transparency laws.

State Law Restrictions:

Minnesota: Regardless of where you practice or reside, if you are a Minnesota-licensed practitioner with prescribing privileges, then you may not consume any food or beverage associated with this event.

Vermont: Regardless of where you practice or reside, if you are a Vermont-licensed HCP, you may not consume any food or beverage associated with this event. Additionally, if you are an employee/agent of a Vermont HCP (e.g., PAs, non-prescribing nurses, etc.), regardless of where you practice or reside, you may not consume any food or beverage associated with this event.

Pfizer does not provide or pay for alcohol in connection with any Pfizer-sponsored program.

CGRP, calcitonin gene-related peptide; HCP, healthcare provider; PA, physician assistant.

This promotional program is for US healthcare professionals only.

© 2026 Pfizer Inc. All rights reserved. October 2026. PP-NNT-USA-5923

Pfizer